The US Food and Drug Administration will now require Covid-19 vaccines from Pfizer/BioNTech and Moderna to use expanded warning labels with more information about the risk of a rare heart condition after vaccination.

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter.

The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials.

Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of recommending that COVID-19 vaccines for 2025-26 should target newer strains of the JN.1 variant.

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at higher risk of severe disease, but will require vaccine makers to conduct major new clinical trials before approving them for wider use.

In a major policy shift, federal health officials anticipate the shots will be made available to adults 65 and older as well as children and younger adults who have one or more risk factors that make them more vulnerable to severe COVID-19.

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy

As the COVID pandemic took hold in 2020, federal lawmakers created a series of loans to help struggling businesses stay afloat through the Coronavirus Aid, Relief, and Economic Security Act.